Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

Novel Therapies for the Treatment of Follicular Lymphoma

July 24th 2018

Personalized Immunotherapy in Follicular Lymphoma

July 24th 2018

R2 Regimen: RELEVANCE and AUGMENT Studies

July 24th 2018

PcP Prophylaxis in Relapsed Follicular Lymphoma

July 24th 2018

PI3K-Targeted Therapy for R/R Follicular Lymphoma

July 24th 2018

R/R Follicular Lymphoma: Second and Third-Line Options

July 24th 2018

Timing of Second-Line Therapy in Follicular Lymphoma

July 24th 2018

Maintenance Therapy Outcomes in Follicular Lymphoma

July 24th 2018

Follicular Lymphoma: Results from Phase II GALLIUM Study

July 24th 2018

Immunochemotherapy Approaches for Follicular Lymphoma

July 24th 2018

Risk Classification and Assessment in Follicular Lymphoma

July 24th 2018

Follicular Lymphoma Diagnostic Workup

July 24th 2018

Ibrutinib/Rituximab Emerges as New Standard in Waldenstrom Macroglobulinemia

July 23rd 2018

Results from the phase III iNNOVATE trial established the combination of ibrutinib plus rituximab as the new standard of care in Waldenström macroglobulinemia.

Dr. Vose Discusses the Importance of Genomic Analysis in NHL

July 18th 2018

Julie M. Vose, MD, MBA, professor, internal medicine, chief, Division of Oncology & Hematology, University of Nebraska Medical Center, discusses the importance of genomic analysis in patients with non-Hodgkin lymphoma.

Navigating the Toxicities of Novel-Novel Combinations in Lymphoma

July 18th 2018

Combinations of novel drugs in lymphomas have the potential to overcome resistance to therapy but come with sometimes unexpected adverse events that demand careful monitoring.

CAR T-cell Therapies Offer Hope for DLBCL

July 15th 2018

Chimeric antigen receptor T-cell therapies have quickly moved from early phase clinical trials to FDA approval for diffuse large B-cell lymphoma, with research now exploring ways to shift these agents earlier in the treatment paradigm.

Frontline Ibrutinib Plus R-CHOP Misses Primary Endpoint in Phase III DLBCL Trial

July 11th 2018

Combining ibrutinib with standard R-CHOP did not improve event-free survival versus R-CHOP alone in the first-line setting for patients with diffuse large B-cell lymphoma.

Dr. Flinn on CAR T-Cell Therapy in Non-Hodgkin Lymphoma

July 11th 2018

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses chimeric antigen receptor (CAR) T-cell therapy in non-Hodgkin lymphoma (NHL).

PFS Valid Surrogate Endpoint for Overall Survival in Frontline DLBCL

July 11th 2018

Progression-free survival appears to be a surrogate endpoint for overall survival in patients undergoing first-line treatment for diffuse large B-cell lymphoma, according to results from a large pooled analysis.

Dr. Abramson Discusses Lisocabtagene Maraleucel in NHL

July 10th 2018

Jeremy S. Abramson, MD, clinical director, Center for Lymphoma, Massachusetts General Hospital, discusses lisocabtagene maraleucel (JCAR017; liso-cel) as a treatment for patients with non-Hodgkin lymphoma.